Companies /Financial Services

SLR Investment Corp

NASDAQ: SLRC Asset Management
$12.52
â–² $0.04 (+0.32%) today
Markets closed · 8:02pm ET

Q2 2025 Earnings

Reported Aug 5, 2025, 4:45pm ET · SEC source
$0.40
Miss −0.77%
EPS · est. $0.40
$53.9M
Beat +1.29%
Revenue · est. $53.2M
−0.4%
Trailing market
SLRC vs S&P since report
6 quarters
Consecutive EPS misses

Market Reaction

% change · around the report
0+2%+4%Aug 5Aug 6report 4:45pm ETearnings+0.7%+3.5%
0+2%+4%Aug 5Aug 6earnings+0.7%+3.5%
SLRC +3.5%S&P 500 +0.7%
0+2%+4%Aug 5Aug 6report 4:45pm ETearnings+1.3%+3.5%
0+2%+4%Aug 5Aug 6earnings+1.3%+3.5%
SLRC +3.5%NASDAQ +1.3%
0+2%+4%Aug 4Aug 13report 4:45pm ETearnings+2.7%+4.1%
0+2%+4%Aug 4Aug 13earnings+2.7%+4.1%
SLRC +4.1%S&P 500 +2.7%
0+2%+4%Aug 4Aug 13report 4:45pm ETearnings+3.6%+4.1%
0+2%+4%Aug 4Aug 13earnings+3.6%+4.1%
SLRC +4.1%NASDAQ +3.6%
+3.27%
Day of report
−1.09%
Next session
+0.61%
One week
+2.19%
30 days

S&P 500 over the same 30 days: +2.54%.

Did SLRC Beat Earnings? Q2 2025 Results

SLR Investment Corp. delivered a mixed second quarter for 2025, posting total investment income of $53.91 million, beating the $53.23 million consensus by 1.29% and rising 22.7% from a year ago, while earnings per share of $0.40 fell just shy of the $0.40 consensus estimate by 0.77%. The slight EPS miss reflected a year-over-year decline in net investment income, from $0.45 per share in Q2 2024 to $0.40, driven by a smaller average income-producing portfolio and lower index rates. Partially offsetting that pressure, net realized and unrealized gains of $2.62 million reversed a prior-year loss of $1.09 million, lifting net assets from operations to $24.23 million, or $0.44 per share. The quarter's clearest strategic signal was the continued shift toward specialty finance, with asset-based lending now representing over 80% of portfolio fair value and generating record originations. Management sees that momentum continuing, with more than $650 million in available capital deployed toward an expanding specialty finance pipeline, and no refinancing obligations until December 2026.

Key Takeaways
  • Record ABL originations in Q2 2025 driving portfolio mix shift toward specialty finance
  • Over 80% of portfolio fair value in specialty finance loans
  • Strong credit quality with non-accruals at 0.3% of fair value
  • 97.8% of portfolio rated 1 or 2 on internal risk scale
  • Net portfolio activity of $180.1 million driven by $567.1 million originations vs $387.0 million repayments
  • Asset-based lending contributed 42.9% of total investment income

“We are pleased to report that our specialty finance businesses have continued to expand their pipelines in what has been a challenging investment environment for private credit more broadly. Our record ABL originations for the second quarter furthered our strategic goal of shifting the portfolio mix to predominantly specialty finance investments. Today, over 80% of our portfolio fair value consists of specialty finance loans, which we believe carry attractive risk adjusted returns and offer downside protection through collateral coverage. We are continuing to see demand for our asset-based financing solutions from issuers navigating the current uncertain economic climate.”

SLR Investment CEO, on the earnings call

Forward Guidance & Outlook

The company expects continued demand for its asset-based financing solutions from issuers navigating the uncertain economic climate. Specialty finance pipelines are expanding despite a challenging investment environment for private credit. SLRC intends to continue shifting its portfolio mix toward specialty finance investments. The company has over $650 million of available capital to fund growth. No near-term refinancing obligations exist, with the next unsecured notes maturity in December 2026.

SLRC YoY Financials

Q2 2025 vs Q2 2024 · SEC filings Q2 2024 Q2 2025
$0$20.0M$40.0M$43.9M$53.9MRevenue$23.2M$21.6MNet Income$23.2M$21.6MOperating Income
$0$20.0M$40.0MRevenueNet IncomeOperating Income

SLRC Revenue by Segment

Asset-Based Lending
Equipment Financings
Sponsor Finance (Cash Flow Loans)
Life Science Loans
Asset-based Lending$23.1M
Sponsor Finance$14.7M
Equipment Finance$9.6M
Life Science Finance$6.5M

Figures from SEC filings and company reports. Not investment advice.